Marksans Pharma Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Benzonatate Capsules USP, 100 mg and 200 mg (Rx). This approval marks another important milestone in the company’s ongoing efforts to expand its presence in regulated markets and strengthen its portfolio of high-quality, affordable generic medicines.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug, Tessalon Capsules, 100 mg and 200 mg. Benzonatate is a non-narcotic antitussive medication widely prescribed for the symptomatic relief of cough associated with respiratory conditions. It works by numbing stretch receptors in the respiratory tract, thereby reducing the cough reflex and providing relief in cases such as bronchitis, pneumonia, and other lung infections.
With this approval, Marksans Pharma is well positioned to address a consistent demand for effective cough management therapies in the United States. The addition of Benzonatate Capsules to the company’s product portfolio reinforces its commitment to delivering safe, effective, and accessible medications to patients while maintaining high standards of manufacturing and regulatory compliance.
The US generics market continues to present significant opportunities, particularly for products that address common therapeutic needs. Marksans Pharma’s growing pipeline of approved ANDAs reflects its strategic focus on identifying and developing products with strong market potential and sustainable demand.
The company remains committed to leveraging its research and development capabilities, along with its manufacturing expertise, to expand its global footprint. By continuously enhancing its product offerings, Marksans Pharma aims to create long-term value for its stakeholders while contributing to improved patient outcomes.
This latest approval underscores the company’s ability to successfully navigate complex regulatory pathways and deliver quality healthcare solutions. Marksans Pharma will continue to pursue similar opportunities in the future, strengthening its position as a reliable partner in the global pharmaceutical industry.
